Claim: There's a promising new HIV vaccine candidate in the pipeline
Verdict: SUPPORTS

Retrieved passages:
title: HIV vaccine
text: and a gp120 protein adapted for the subtype C HIV virus common in sub-Saharan Africa, and initial results showed that those who received the vaccine regimen produced strong immune responses early on. Other strategies that have progressed to phase I trials in uninfected persons include peptides, lipopeptides, DNA, an attenuated Salmonella vector, p24, etc. Specifically, candidate vaccines that induce one or more of the following are being sought: In 2011, researchers in National Biotech Centre in Madrid unveiled data from the Phase I clinical trial of their new vaccine, MVA-B. The vaccine was effective in inducing an immunological response in

title: HIV/AIDS in China
text: an effective vaccine that can offer long-term protection against the wide spectrum of HIV variants that exist. Despite the fact that there are now more than 30 vaccine candidates in clinical trials (in the world), and three of these are in advance stage testing (phase IIb and phase III), many obstacles still lie in the way of the development of a truly effective HIV preventive vaccine. The genetic diversity of HIV presents an enormous challenge for researchers. And, because the virus has the ability to evade neutralizing antibodies produced by natural immunity, the standard vaccine strategy of mimicking natural infection

title: Management of HIV/AIDS
text: thought that a vigorous immune response will need to be induced to clear all the remaining infected cells. Current strategies include using cytokines to restore CD4+ cell counts as well as therapeutic vaccines to prime immune responses. One such candidate vaccine is Tat Oyi, developed by Biosantech. This vaccine is based on the HIV protein tat. A brief report of their phase I/II clinical trial reported it was safe and well tolerated in 48 HIV-positive patients. Animal models have shown the generation of neutralizing antibodies and lower levels of HIV viremia. Direct-to-consumer and other advertisements for HIV drugs in the

title: HIV/AIDS research
text: RV 144. In 2009, the researchers reported that this vaccine showed some efficacy in protecting recipients from HIV infection. Results of this trial give the first supporting evidence of any vaccine being effective in lowering the risk of contracting HIV. Another possible vaccine comes from a novel gene therapy that alters the CCR5 co-receptor permanently, preventing HIV from entering cells. Other vaccine trials continue worldwide. One of the most recent and most promising trials was conducted by scientists at The Scripps Research Institute (TSRI) who found a way to attach HIV-fighting antibodies to immune cells, creating a HIV-resistant cell population.

title: HIV vaccine
text: 92% of the healthy subjects. In 2016, results were published of the first Phase I human clinical trial of a killed whole-HIV-1 vaccine, SAV001. HIV used in the vaccine was chemically and physically deadened through radiation. The trial, conducted in Canada in 2012, demonstrated a good safety profile and elicited antibodies to HIV-1. According to Dr. Chil-Yong Kang of Western University's Schulich School of Medicine & Dentistry in Canada, the developer of this vaccine, antibodies against gp120 and p24 increased to 8-fold and 64-fold, respectively after vaccination. "Preventative HIV vaccines" "Therapeutic HIV vaccines" Biosantech developed a therapeutic vaccine called Tat

title: HIV vaccine
text: that has to date prevented clinical development of a live attenuated HIV-1 vaccine. Scientists are researching novel strategies to develop a non-virulent live attenuated HIV-1 vaccine. For example, a genetically modified form of HIV has been created in which the virus' codons (a sequence of three nucleotides that form genetic code) are manipulated to rely on an unnatural amino acid for proper protein translation, which allows it to replicate. Because this amino acid is foreign to the human body, the virus cannot reproduce. Scientists at Scripps Research found a way to attach HIV-fighting antibodies to immune cells, creating an HIV-resistant

title: HIV vaccine
text: Oyi, which targets the tat protein of HIV. It was tested in France in a double-blind Phase I/II trial with 48 HIV-positive patients who had reached viral suppression on Highly Active Antiretroviral Therapy and then stopped antiretrovirals after getting the intradermal Tat Oyi vaccine. "Preventative HIV vaccines" There have been no passive preventative HIV vaccines to reach Phase III yet, but some active preventative HIV vaccine candidates have reached Phase III. "Therapeutic HIV vaccines" No therapeutic HIV vaccine candidates have reached phase 3 testing yet. A July 2012 report of the HIV Vaccines & Microbicides Resource Tracking Working Group estimates

title: HIV vaccine
text: from other clades, though the pattern of recognition was not uniform among volunteers. The canarypox vector is the first candidate HIV vaccine that has induced cross-clade functional CTL responses. The first phase I trial of the candidate vaccine in Africa was launched early in 1999 with Ugandan volunteers. The study determined the extent to which Ugandan volunteers have CTL that are active against the subtypes of HIV prevalent in Uganda, A and D. In 2015, a Phase I trial called HVTN 100, chaired by two South African researchers Linda-Gail Bekker and Fatima Laher, tested the combination of a canarypox vector

title: GeoVax
text: Preliminary results indicate an excellent safety profile and highly reproducible immunogenicity subsequently confirmed by the official publication above in "The Journal of Infectious Diseases". In April 2011, GeoVax Labs, Inc. in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN) announced an expansion of the current Phase 2a clinical trial to include a new component. The new trial is HVTN 094 and will be conducted by the HIV Vaccine Trials Network. "Specifically, the HVTN plans to clinically test a novel vaccine product

title: HIV/AIDS research
text: to confer protection against subsequent exposures to HIV, thus reducing the likelihood that the person would become infected by HIV. Currently, no effective HIV vaccine exists. Various HIV vaccines have been tested in clinical trials almost since the discovery of HIV. Only a vaccine is thought to be able to halt the pandemic. This is because a vaccine would cost less, thus being affordable for developing countries, and would not require daily treatment. However, after over 20 years of research, HIV-1 remains a difficult target for a vaccine. In 2003 a clinical trial in Thailand tested an HIV vaccine called

title: Duke University Human Vaccine Institute
text: of an AIDS vaccine. Led by Barton Haynes, MD this effort has had a major effect on the progress of the entire field of HIV vaccine development, and has pointed the way to new progress. A recent example of this DHVI-led progress has been the leadership of the DHVI in the immune correlates analysis of the RV144 vaccine trial. RV144 showed an estimated vaccine efficacy of 31.2%, and the study of the correlates of immunity is a critical opportunity for the field to understand why this trial worked, in order to make future vaccines perform better. Over the next 7

title: Chang Yi Wang
text: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allerg Immunol 1997; 15:41-48. 32. Singh M, McGee JP, Li XM, Koff W, Zamb T, Wang CY and O’Hagan DT. Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine. J Pharmaceut Sci 1997; 86:1229. 33. Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY and O’Hagan DT. Controlled release microparticles as a single dose hepatitis B vaccine; evaluation of immunogenicity in mice. Vaccine 1997; 15:475. 34. Singh M, Li XM, Wang HY, McGee JP, Zamb T, Koff

title: University of Western Ontario
text: HIV/AIDS vaccine. SAV001-H is the first and only preventative HIV vaccine based on a genetically modified killed whole HIV-1 virus. The United States Food and Drug Administration (FDA) Phase I clinical trial was completed in August 2013 and reported no serious adverse effects while boosting antibodies in the volunteers. The vaccine SAV001-H holds tremendous promise, having already proven to stimulate strong immune responses in preliminary toxicology tests. It is the only HIV vaccine under development in Canada, and one of only a few in the world. The two main student unions on administrative and policy issues is the University Students'

title: HIV vaccine
text: may be possible. Some, but certainly not all, HIV-infected individuals naturally produce broadly neutralizing antibodies which keep the virus suppressed and these people remain asymptomatic for decades. Potential broadly neutralizing antibodies have been cloned in the laboratory (monoclonal antibodies) and are being tested in passive vaccination clinical trials. Many trials have shown no efficacy but thus far, one HIV vaccine regimen, RV 144, has been shown to prevent HIV in some individuals in Thailand. The urgency of the search for a vaccine against HIV stems from the AIDS-related death toll of over 35 million people since 1981. In 2002, AIDS

title: HIV vaccine
text: that $845 million was spent on AIDS vaccine research in 2011. Economic issues with developing an AIDS vaccine include the need for advance purchase commitment (or advance market commitments) because after an AIDS vaccine has been developed, governments and NGOs may be able to bid the price down to marginal cost. Theoretically, any possible HIV vaccine must inhibit or stop the HIV virion replication cycle. The targets of a vaccine could be the following stages of the HIV virion cycle: Therefore, the following list comprises the current possible approaches for an HIV vaccine: Here, “damage” means inhibiting or stopping the

title: Vaccine Research Center
text: at the Vaccine Research Center found that two human HIV antibodies, named VRC01 and VRC03, could potentially be used against a wide range of types and mutations of HIV in the design of a preventive HIV vaccine for human use, as well as in the formation of better antiretroviral therapy drug cocktails. The discovery, a potentially landmark one in the drive to find a vaccine for AIDS should it be validated and further improved, will be featured in the journal Science. The Vaccine Research Center has multiple Research Laboratories (currently Viral Pathogenesis, Virology, and Immunology), and Research Sections (Humoral Immunology,

title: Chang Yi Wang
text: using synthetic peptides delivered in emulsions – critical role of the formulation procedure. Vaccine 1997; 15:1773-1778. 30. Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, Cheng H, Li M, Wang CY, et al. International clinical trials of HIV vaccines: II. Phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. Asian Pac J Allergy Immunol 1997; 15: 105-113. 31. Phanuphak P. Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S, Leesavan A, Forrest BD, Hanson CV, Li ML, Wang, CY, et al. International clinical trials of HIV vaccines:

title: SAV001
text: placebo-controlled study, following intramuscular administration to 33 chronic HIV-1 infected individuals under the treatment with HAART. The study was completed in August 2013 and reported no serious adverse effects while boosting antibodies in the volunteers injected with SAV001-H vaccines. According to the researchers, the antibody against gp120 surface antigen and P24 capsid antigen increased up to 6-fold and 64-fold, respectively, and the increased level of antibody was continued throughout the 52-week study period. Moreover, broadly neutralizing antibodies were found in some blood samples of the participants. Phase II clinical trial The Phase II clinical trial is expected to begin in

title: Stephen C. Harrison
text: and several components of HIV. He has also turned some of his research attention to even more complex assemblies, such as clathrin-coated vesicles. He led the Structural Biology team at the Center for HIV/AIDS Vaccine Immunology (CHAVI) when it received National Institute of Allergy and Infectious Diseases (NIAID) funding of around $300 million to address key immunological roadblocks to HIV vaccine development and to design, develop and test novel HIV vaccine candidates. He is a member of American Academy of Arts and Sciences, National Academy of Sciences, American Philosophical Society, European Molecular Biology Organization, American Crystallographic Association and American Association

title: AIDSVAX
text: designed to provoke the production of antibodies in subjects that would strip the gp120 protein off of the HIV viral particles, effectively disabling the virus so that it could not bind to or invade susceptible cells. Then, another group, infected with a second strain of HIV, A244, was discovered in 1995, and a revised, bivalent version of the vaccine was produced that combined elements of both MN and A244. Phase I and Phase II tests of the first version were promising, showing excellent safety in chimpanzees and humans and provoking production of HIV MN and A244 antibodies in 99% of